Clinical and Experimental Medicine

, Volume 9, Issue 3, pp 243–248 | Cite as

Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile

  • Michela Zanetti
  • Alessandra Bosutti
  • Clara Ferreira
  • Pierandrea Vinci
  • Gianni Biolo
  • Maurizio Fonda
  • Matteo Valente
  • Luigi Cattin
  • Gianfranco Guarnieri
  • Rocco Barazzoni
Original Article

Abstract

Metabolic syndrome is characterized by increased cardiovascular risk. Pentraxin 3 (PTX3), an acute phase protein, is involved in atherosclerosis. No information is available on PTX3 plasma concentrations in metabolic syndrome and on its associations with metabolic alterations and subclinical atherosclerosis. The aim of this study was to assess PTX3 plasma levels in metabolic syndrome patients compared to control subjects and their potential associations with anthropometric and clinical components of the syndrome as well as with carotid artery intima-media thickness (cIMT), a marker of subclinical atherosclerosis. Plasma was obtained from metabolic syndrome patients (NCEP-ATP III criteria n = 41, 20 M/21F) and by age-matched control subjects (n = 32, 16 M/16F). PTX3 was measured using sandwich ELISA and cIMT with ultrasound. Compared to those of the control subjects, plasma levels of PTX3 were higher (+~100%, P = 0.0009) in metabolic syndrome patients. In univariate analysis, plasma PTX3 was negatively (P = 0.005) associated with high-density lipoprotein (HDL) cholesterol and positively (P = 0.046) with plasma triglycerides and with cIMT (P = 0.045) in the patients (n = 41). In multivariate analysis the direct association between PTX3 and cIMT was no longer significant after correction for HDL. None of these associations were detected in the control patients. These data demonstrate that PTX3, a novel marker of vascular disease, is higher in patients with metabolic syndrome associated with subclinical atherosclerosis. In addition, PTX3 is significantly independently correlated with low HDL cholesterol, but not with cIMT, suggesting a novel association between PTX3 and atherogenic lipid profile.

Keywords

Metabolic syndrome Pentraxin 3 HDL cholesterol Atherosclerosis 

References

  1. 1.
    Koh KK, Han SH, Quon MJ (2005) Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46:1978–1985PubMedCrossRefGoogle Scholar
  2. 2.
    Malik S, Wong ND, Franklin SS et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:1245–1250PubMedCrossRefGoogle Scholar
  3. 3.
    Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRefGoogle Scholar
  4. 4.
    McNeill AM, Rosamond WD, Girman CJ et al (2004) Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol 94:1249–1254PubMedCrossRefGoogle Scholar
  5. 5.
    Grundy SM (2006) Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone 8:S21–S27PubMedCrossRefGoogle Scholar
  6. 6.
    Mantovani A, Garlanda C, Bottazzi B et al (2006) The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 45:326–330PubMedCrossRefGoogle Scholar
  7. 7.
    Napoleone E, di Santo A, Peri G et al (2004) The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 76:203–209PubMedCrossRefGoogle Scholar
  8. 8.
    Napoleone E, Di Santo A, Bastone A et al (2002) Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 22:782–787PubMedCrossRefGoogle Scholar
  9. 9.
    Klouche M, Peri G, Knabbe C et al (2004) Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175:221–228PubMedCrossRefGoogle Scholar
  10. 10.
    Breviario F, d’Aniello EM, Golay J et al (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267:22190–22197PubMedGoogle Scholar
  11. 11.
    Rolph MS, Zimmer S, Bottazzi B et al (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22:e10–e14PubMedCrossRefGoogle Scholar
  12. 12.
    Kotooka N, Inoue T, Fujimatsu D et al (2008) Pentraxin 3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197:368–374PubMedCrossRefGoogle Scholar
  13. 13.
    Peri G, Introna M, Corradi D et al (2000) PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102:636–641PubMedGoogle Scholar
  14. 14.
    Latini R, Maggioni AP, Peri G et al (2004) Lipid Assessment Trial Italian Network (LATIN) investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354PubMedCrossRefGoogle Scholar
  15. 15.
    Boehme M, Kaehne F, Kuehne A et al (2007) Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant 22:2224–2229PubMedCrossRefGoogle Scholar
  16. 16.
    Malaponte G, Libra M, Bevelacqua Y et al (2007) Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines. Int J Mol Med 20:471–481PubMedGoogle Scholar
  17. 17.
    Suzuki S, Takeishi Y, Niizeki T et al (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 155:75–81PubMedCrossRefGoogle Scholar
  18. 18.
    National Institutes of Health Third Report of the National Cholesterol Education (2001) Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary, Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute (NIH publ. no. 01-3670)Google Scholar
  19. 19.
    Hampel DJ, Pratschke J, May G et al (2006) Living kidney donation: anemia and inflammation in the early postoperative period. Transplant Proc 38:661–663PubMedCrossRefGoogle Scholar
  20. 20.
    Boden WE (2000) High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 86:19L–22LPubMedCrossRefGoogle Scholar
  21. 21.
    Hong Y, Jin X, Mo J et al (2007) Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality—results of prospective analysis for the atherosclerosis risk in communities study. J Intern Med 262:113–122PubMedCrossRefGoogle Scholar
  22. 22.
    Wallenfeldt K, Hulthe J, Fagerberg B (2005) The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow up. J Intern Med 258:28–37PubMedCrossRefGoogle Scholar
  23. 23.
    Alberti A, Gilardini L, Zulian A et al (2008) Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis May 15 (Epub ahead of print)Google Scholar
  24. 24.
    Norata GD, Marchesi P, Pirillo A et al (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscl Thromb Vasc Biol 28:925–931PubMedCrossRefGoogle Scholar
  25. 25.
    Dichtl W, Nilsson L, Goncalves I et al (1999) Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 84:1085–1094PubMedGoogle Scholar
  26. 26.
    Ting HJ, Stice JP, Schaff UY et al (2007) Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res 100:381–390PubMedCrossRefGoogle Scholar
  27. 27.
    Lekakis JP, Papamichael CM, Cimponeriu AT et al (2000) Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol 85:949–952PubMedCrossRefGoogle Scholar
  28. 28.
    Mack WJ, LaBree L, Liu C et al (2000) Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis 150:371–379PubMedCrossRefGoogle Scholar
  29. 29.
    Bosutti A, Grassi G, Zanetti M et al (2007) Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients. Clin Exp Med 7:16–23PubMedCrossRefGoogle Scholar
  30. 30.
    Camozzi M, Zacchigna S, Rusnati M et al (2005) Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 25:1837–1842PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Michela Zanetti
    • 1
  • Alessandra Bosutti
    • 1
  • Clara Ferreira
    • 1
  • Pierandrea Vinci
    • 1
  • Gianni Biolo
    • 1
  • Maurizio Fonda
    • 2
  • Matteo Valente
    • 2
  • Luigi Cattin
    • 2
  • Gianfranco Guarnieri
    • 1
  • Rocco Barazzoni
    • 1
  1. 1.Clinica Medica Generale, DSCMTUniversity of TriesteTriesteItaly
  2. 2.Diabetes Center, UCO III MedicaAzienda Ospedaliero-Universitaria “Ospedali Riuniti” TriesteTriesteItaly

Personalised recommendations